Continuing Education Credits Are Not Awarded for These Sessions.
Details
June 22 @ 12:30 pm – 1:30 pm CDT
Product Theater 2
Presented by: Corcept Therapeutics
Program Description
Discover how data from the CATALYST study is reshaping clinical practice, with impact on hyperglycemia management and patient outcomes in endogenous hypercortisolism.
Join our panelists for a robust and interactive discussion!
Panelists will include:
- Ralph DeFronzo, MD
- Christopher Lucci, MD
- Eden M. Miller, DO, FBOM
This program is not part of the 85th Scientific Sessions of the American Diabetes Association® (ADA) as planned by the ADA. This event is neither sponsored nor endorsed by the ADA. This event does not qualify for continuing medical education (CME) credit.
Corcept leads the field in the research and development of selective glucocorticoid receptor (GR) antagonists, having discovered more than 500 proprietary molecules since being founded in 1998. Corcept is committed to improving patient lives through the discovery and development of drugs that address serious unmet medical needs related to excess cortisol activity.
Panelists
Ralph DeFronzo, MD
University of Texas
Chief Diabetes Division
San Antonio, TX
Christopher Lucci, MD
Diabetes and Cardiovascular of Rockport
Owner and Founder
Rockport, TX
Eden M. Miller, DO, FBOM
Diabetes & Obesity Care LLC
Chief Executive Officer
Bend, OR